Cargando…

Unexpected favorable outcome to sintilimab monotherapy in a relapse pancreatic ductal adenocarcinoma patient with high tumor mutational burden: a case report

The reason that immune checkpoint inhibitors have not been widely applied to pancreatic cancer treatment is probably because of low immunogenicity or dense stromal fibrosis. Recently, only pembrolizumab was recommended for DNA mismatch repair deficiency or high microsatellite instability by National...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Fan, Li, Xiaomin, Liu, Haisheng, Liu, Rongfeng, Zhou, Zhiguo, Zhang, Yi, Chen, Jingli, Tian, Ye, Pan, Chaohu, Meng, Qingju, Liu, Yibing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481288/ https://www.ncbi.nlm.nih.gov/pubmed/35946538 http://dx.doi.org/10.1097/CAD.0000000000001334

Ejemplares similares

Immunotherapy Combined with Chemotherapy in Relapse Metaplastic Breast Cancer
por: Chen, Ling, et al.
Publicado: (2023)

Case report: Undifferentiated sarcoma with multiple tumors involved in Lynch syndrome: Unexpected favorable outcome to sintilimab combined with chemotherapy
por: Liu, Jiaying, et al.
Publicado: (2022)

Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR‐mutated non‐small cell lung cancer patient: A case report
por: Zhang, Yiruo, et al.
Publicado: (2020)

Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study
por: Zheng, Fei, et al.
Publicado: (2023)

Combination of Serum Test and Questionnaire in Early Gastric Cancer Screening
por: Li, Qiang, et al.
Publicado: (2022)

Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report
por: Zeng, Shu-Ying, et al.
Publicado: (2022)

Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma
por: Yang, Huayu, et al.
Publicado: (2022)

Recent updates on Sintilimab in solid tumor immunotherapy
por: Liu, Xuhong, et al.
Publicado: (2020)

Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients
por: Fan, Zhirong, et al.
Publicado: (2020)

11, 13-Dehydro Lactone Moiety in Gynecologic Cancer Cells
por: LIU, Yibing, et al.
Publicado: (2020)

Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK- LIMS1 Fusion: A Case Report
por: Shi, Junmei, et al.
Publicado: (2023)

Sintilimab: Pneumonitis: case report
Publicado: (2021)

Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
por: Jia, Ru, et al.
Publicado: (2022)

Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab
por: Shi, Yuankai, et al.
Publicado: (2020)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

EDP-M plus sintilimab in the treatment of adrenocortical carcinoma: a case report
por: Zhang, Zhipeng, et al.
Publicado: (2022)

Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
por: Tao, Rong, et al.
Publicado: (2021)

Cardiac Troponin T (TNNT2) plays a potential oncogenic role in colorectal carcinogenesis
por: Liu, Yifan, et al.
Publicado: (2023)

Sintilimab for the treatment of non-small cell lung cancer
por: Zhang, Lin, et al.
Publicado: (2022)

Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial—a study protocol of clinical trial
por: Li, Ruyuan, et al.
Publicado: (2022)

METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma
por: Lu, Liting, et al.
Publicado: (2022)

Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report
por: Lye, Ya-lei, et al.
Publicado: (2023)

Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis
por: Feng, Li, et al.
Publicado: (2021)

Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study
por: Zhao, Lei, et al.
Publicado: (2022)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020)

A rare presentation of Sintilimab-induced swelling along the vessels: Case report
por: Liu, Liqiong, et al.
Publicado: (2023)

Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data
por: Tang, Hui, et al.
Publicado: (2022)

Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
por: Fujita, Kohei, et al.
Publicado: (2021)

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China
por: Yang, Wenyu, et al.
Publicado: (2023)

Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review
por: Huang, Wenying, et al.
Publicado: (2023)

Sintilimab: Aggravation of Coronavirus disease 2019: case report
Publicado: (2021)

Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma
por: Dai, Lei, et al.
Publicado: (2021)

P16: DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY
por: Terpos, E, et al.
Publicado: (2022)

Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer
por: Zhang, Shuang, et al.
Publicado: (2018)

Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report
por: Xu, Jingyan, et al.
Publicado: (2021)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Peng, Ye, et al.
Publicado: (2022)

Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers
por: Liu, Youqiang, et al.
Publicado: (2022)

A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma
por: Gong, Yinhua, et al.
Publicado: (2023)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gnuunr9ejsu44taeurht73j6ub